Efficacy of Treating Post-Traumatic Epilepsy in Children With Ketogenic Diet

Hyoung Won Choi1,2, Sonam Bhalla1,2, Philip Holt1,2

  • 1Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.

Insights

The ketogenic diet effectively reduced seizures in children with post-traumatic epilepsy (PTE). This study suggests the ketogenic diet is a viable treatment for managing seizures following traumatic brain injury (TBI) in pediatric patients.

Area of Science:

  • Neurology
  • Pediatrics
  • Nutritional Science

Background:

  • Post-traumatic epilepsy (PTE) is a significant complication following traumatic brain injury (TBI).
  • Effective seizure control strategies for pediatric PTE are crucial for improving patient outcomes.
  • The ketogenic diet is a well-established therapy for drug-resistant epilepsy.

Purpose of the Study:

  • To evaluate the efficacy of the ketogenic diet in controlling seizures in children diagnosed with post-traumatic epilepsy.
  • To assess the response rate to ketogenic diet therapy in a cohort of pediatric patients with PTE.

Main Methods:

  • Retrospective chart review of pediatric patients with PTE treated at the Children's Hospital of Atlanta ketogenic program.
  • Inclusion criteria: patients with TBI treated with ketogenic diet for at least 3 months for PTE.
  • Data collected included patient demographics, TBI characteristics, seizure history, and response to ketogenic diet.

Main Results:

  • The study analyzed 13 children with PTE (10 males), with a mean age of 5 years 1 month at diet initiation.
  • The median duration of seizures prior to ketogenic diet was 2 years; 11 out of 13 patients had severe TBI, often from non-accidental trauma.
  • A significant response rate of 69% (9/13) was observed, indicating seizure reduction with ketogenic diet treatment.

Conclusions:

  • The ketogenic diet demonstrates effectiveness in reducing seizure burden among children with post-traumatic epilepsy.
  • This study provides Class IV evidence supporting the ketogenic diet as a therapeutic option for pediatric PTE.
  • Further research may explore long-term outcomes and optimal implementation of ketogenic diet in this population.

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.7K
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.3K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.2K
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
2.5K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.7K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
405